Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
On November 6, 2025, Smith & Nephew plc announced a significant transaction involving the purchase of American Depositary Shares (ADS) by Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, on the New York Stock Exchange. This transaction, disclosed under the UK Market Abuse Regulation, highlights the company’s ongoing strategic activities and could indicate confidence in the company’s future performance, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SNN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company that specializes in the development and manufacturing of advanced medical devices, including orthopedics, sports medicine, and wound management products. The company is focused on providing innovative solutions to improve patient outcomes and is a key player in the healthcare industry.
Average Trading Volume: 667,925
Technical Sentiment Signal: Buy
Current Market Cap: $15.51B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.